论文部分内容阅读
目的 观察干扰素α - 1b(IFNα - 1b)与利巴韦林 (ribavirin)联合治疗慢性丙型肝炎 (CHC)的疗效及安全性。方法 6 4例CHC随机分为联合治疗组 (IFNα - 1b 加利巴韦林 ,30例 )与对照组 (单用IFNα - 1b,34例 ) ,观察两组治疗前后的疗效和毒副作用。结果 联合治疗组临床症状体征的缓解率为 93.33% ,病毒应答率为 6 3.33% ;对照组分别为 85 .30 %、47.0 6 % ,两组无显著差异 (P >0 .0 5 )。随访 6个月联合治疗组的持续应答率为 40 .0 0 % ,对照组为 14.71% ,有显著差异 (P <0 .0 5 )。联合治疗组副作用除贫血较对照组明显外 ,其他与对照组相仿。结论 干扰素联合利巴韦林治疗CHC较单用干扰素远期疗效显著且耐受性好
Objective To observe the efficacy and safety of interferon α - 1b (IFNα - 1b) combined with ribavirin in the treatment of chronic hepatitis C (CHC). Methods Sixteen CHC patients were randomly divided into combined treatment group (IFNα - 1b plus ribavirin, 30 cases) and control group (IFNα - 1b alone, 34 cases). The curative effect and side effect of the two groups were observed before and after treatment. Results The remission rate of clinical symptoms and signs was 93.33% in the combined treatment group and the viral response rate was 6 3.33%. The control group was 85.30% and 47.0 6% respectively, with no significant difference between the two groups (P> 0.05). The follow-up of 6 months in the combination therapy group, the sustained response rate was 40.0%, the control group was 14.71%, there was a significant difference (P <0.05). In addition to the side effects of combination therapy group was significantly anemic compared with the control group, the other similar to the control group. Conclusion Interferon combined with ribavirin treatment of CHC than single interferon long-term efficacy and tolerability